Business Wire

VA-INTELSAT

26.6.2024 17:01:35 CEST | Business Wire | Press release

Share
Intelsat, Starfish Space Reach Deal for Satellite Servicing Mission

Intelsat, operator of the world’s largest integrated satellite and terrestrial network, signed a contract for a Starfish Otter servicing vehicle to provide life extension services to an Intelsat geostationary satellite, beginning in 2026. This landmark agreement reinforces Intelsat’s commitment to utilizing satellite servicing technologies to maximize the value its satellites can provide to customers and will mark Starfish’s first mission to provide services to a commercial satellite operator with Otter.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626723807/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Starting in 2026, Starfish Space’s Otter will dock with a retired Intelsat satellite during a checkout campaign before maneuvering to dock with and service one of Intelsat’s operational satellites. (Courtesy: Starfish Space).

“For six decades, Intelsat has shown commitment to innovation and leveraging new technologies from throughout the industry,” said Jean-Luc Froeliger, Intelsat's Senior Vice President of Space Systems. “By engaging with emerging ventures, we create unique value for Intelsat while fostering a dynamic and competitive environment that drives advancement in space systems. Starfish is the perfect example of this kind of progress, and we look forward to utilizing the services provided by their Otter satellite to maximize the value the world’s largest geostationary satellite fleet can deliver for our customers.”

Intelsat has been a pioneer of extending satellite missions, signing its first agreement for satellite life extension in 2016, and procuring multiple additional life extension missions in recent years. The contract between Intelsat and Starfish represents a significant step for both companies, expanding the market for satellite servicing, and pushing the industry towards a new paradigm for satellite operations. With its Otter spacecraft, Starfish Space utilizes a small satellite architecture and breakthrough hardware and software technologies to provide rapid, flexible, and cost-effective on-orbit servicing missions for satellites.

Starfish will begin its first servicing mission for Intelsat in 2026. Initially, Otter will dock with and maneuver a retired Intelsat satellite in geostationary graveyard orbit. Following this initial operation, Otter will proceed to dock with and provide life extension service to an operational Intelsat satellite, using its onboard propulsion system to keep the client satellite in operational orbit for additional years of life.

“Starfish Space is delighted to be supporting Intelsat with services provided by Otter,” said Dr. Trevor Bennett, Co-Founder of Starfish Space. “They are an incredible team at the forefront of the industry and the Otter will help them deliver even more to their customers. We're also excited that this will be the first of many Otters that will make on-orbit servicing a standard part of satellite operations.”

About Intelsat

Intelsat’s global team of professionals is focused on providing seamless and secure, satellite-based communications to government, NGO and commercial customers through the company’s next-generation worldwide network and managed services. Bridging the digital divide by operating one of the world’s largest and most advanced satellite fleet and connectivity infrastructures, Intelsat enables people and their tools to speak over oceans, see across continents and listen through the skies to communicate, cooperate and coexist. Since its founding six decades ago, the company has been synonymous with satellite-industry “firsts” in service to its customers and the planet. Leaning on a legacy of innovation and focusing on addressing a new generation of challenges Intelsat team members now have their sights on the “next firsts” in space as they disrupt the field and lead in the digital transformation of the industry.

About Starfish Space

Starfish Space is developing the Otter servicing vehicle to extend the lives of satellites in geostationary orbit and dispose of space debris in low-Earth orbit. Starfish has secured contracts for its first Otter missions with Intelsat and the U.S. Space Force, two of the largest global satellite operators. The company launched its Otter Pup demonstration mission in June 2023 and is now delivering on several satellite RPOD missions including its Otter mission for Intelsat. For more information, please visit starfishspace.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240626723807/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye